Molecular Templates

Molecular Templates

Company profile

About

Molecular Templates (NASDAQ:MTEM) specializes in the discovery and development of next-generation immunotoxins for the treatment of cancer and other serious diseases. Their innovative platform technology, Engineered Toxin Bodies (ETB), is designed to create novel therapeutics that target a variety of cancers. Focused on addressing the limitations of current treatments, Molecular Templates is dedicated to advancing a diverse pipeline of ETB candidates through clinical trials with the goal of improving patient outcomes. Their projects include collaborations with larger pharmaceutical companies to harness this technology in creating more effective and less toxic cancer therapies. With a commitment to innovation and a passion for enhancing patient care, Molecular Templates aims to lead the way in the development of novel oncology treatments.

Snapshot

2001Year founded

92Employees

Austin, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

Austin, US

Products and/or services of Molecular Templates

MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin's lymphoma treatment.
MT-6402, a PD-L1 targeted engineered toxin with potential uses in various carcinoma treatments.
TAK-169, designed to target CD38 for multiple myeloma therapy.
MT-5111, a HER2-targeted engineered toxin body for treating HER2-positive cancers.
MT-0169, focused on targeting CTLA-4 for potential immunotherapy enhancements.
Partnership programs with Takeda Pharmaceutical Company, leveraging engineered toxin bodies for oncology therapeutics.